SCHEMBL3763137

SCHEMBL3763137

O=C(CN1CCN(c2ccc(C(F)(F)F)cc2)CC1)N1CCN(C2CCCC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 1/20 0.55
ME1 P48163 1/20 0.55
ME3 Q16798 1/20 0.55
ALDH1A1 P00352 5/20 0.52
MAPT P10636 5/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
GFER P55789 1/20 0.51
ADAMTS5 Q9UNA0 1/20 0.50
CA12 O43570 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
CCR1 P32246 1/20 0.49
KDM4E B2RXH2 2/20 0.49
HIF1A Q16665 1/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
DEGS1 O15121 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
AKR1C3 P42330 1/20 0.48
HRH3 Q9Y5N1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3769215 0.99 ME2 (0.54) ME2ME1ME3ALDH1A1MAPT
SCHEMBL3773835 0.98 ME2 (0.55) ME2ME1ME3ALDH1A1MAPT
SCHEMBL3777307 0.95 ME2 (0.52) ME2ME1ME3ALDH1A1MAPT
SCHEMBL3767937 0.87 ALDH1A1 (0.48) ME2ME1ME3ALDH1A1MAPT
SCHEMBL13004959 0.87 MEN1 (0.62) ME2ME1ME3ALDH1A1MAPT
SCHEMBL3773978 0.87 POLB (0.60) ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3769985 0.86 POLB (0.59) ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3776110 0.86 MEN1 (0.61) ME2ME1ME3ALDH1A1MAPT
SCHEMBL3773996 0.85 KDM2B (0.51) ALDH1A1MAPTSMN1; SMN2KDM4EMEN1
SCHEMBL3762865 0.85 POLB (0.61) ALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ME2 637/4885ME1 1223/4885ME3 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.